MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$21,621K
Free Cash flow
$18,426K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Net income (loss)
Proceeds from stock option exerc...
Others
Negative Cash Flow Breakdown
Accounts receivable
Purchases of property and equipm...
Inventories
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
8,955
108
1,756
-267
Share-based compensation expense
12,313
11,273
11,260
12,424
Depreciation
2,923
2,889
2,997
3,059
Amortization of intangible assets
2,384
2,384
2,110
2,110
Amortization of deferred financing costs
105
105
119
120
Amortization of investments
-
-
0
0
Loss on debt extinguishment
-
-
0
0
Acquired in-process research and development expense
0
-
1,000
0
Other non-cash adjustments
469
708
648
415
Accounts receivable
8,761
5,019
3,755
-2,989
Inventories
2,871
2,770
-455
2,637
Other current assets
-1,202
5,163
-1,359
205
Accounts payable
3,445
5,572
-1,275
360
Accrued liabilities
3,448
-13,508
3,705
9,124
Other noncurrent assets and liabilities
1,420
575
352
776
Net cash provided by operating activities
22,192
-3,996
20,027
26,716
Sales and maturities of available-for-sale securities
-
-
0
0
Purchases of property and equipment
3,766
3,852
1,602
2,605
Proceeds from sale of property and equipment
-
-
0
0
Acquisitions, including in-process research and development
0
-
1,000
0
Proceeds from capital grant
0
0
0
0
Net cash used in investing activities
-3,766
-3,852
-2,602
-2,605
Proceeds from revolving credit facility, net of financing costs
-
-
0
0
Payments on debt, leases and financing obligation
334
1,194
321
301
Proceeds from financing obligation
-
-
0
6,250
Payment of financing costs and debt fees
2
777
0
0
Proceeds from stock option exercises
-
-
1,367
-
Shares repurchased for payment of taxes on stock awards
314
11,442
228
357
Proceeds from issuance of common stock under employee stock purchase plan
-
-
5,923
-
Proceeds from stock option exercises and employee stock purchase plan
3,912
-4,485
-
392
Net cash used in financing activities
3,262
-13,255
2,098
5,984
Effect of exchange rate changes on cash and cash equivalents
-67
-160
40
-26
Net increase (decrease) in cash and cash equivalents
21,621
-21,263
19,563
30,069
Cash and cash equivalentsbeginning of period
146,165
167,428
147,865
122,721
Cash and cash equivalentsend of period
167,786
146,165
167,428
147,865
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Share-based compensation
expense
$12,313K
(-41.37%↓ Y/Y)
Net income (loss)
$8,955K
(169.22%↑ Y/Y)
Accrued liabilities
$3,448K
(159.12%↑ Y/Y)
Proceeds from stock
option exercises and...
$3,912K
(-7.97%↓ Y/Y)
Accounts payable
$3,445K
(7755.56%↑ Y/Y)
Depreciation
$2,923K
(-51.56%↓ Y/Y)
Amortization of intangible
assets
$2,384K
(-43.52%↓ Y/Y)
Other current assets
-$1,202K
(-181.11%↓ Y/Y)
Other non-cash
adjustments
$469K
(50.80%↑ Y/Y)
Amortization of deferred
financing costs
$105K
(-56.07%↓ Y/Y)
Net cash provided by
operating activities
$22,192K
(109.54%↑ Y/Y)
Net cash used in
financing activities
$3,262K
(147.23%↑ Y/Y)
Canceled cashflow
$13,052K
Canceled cashflow
$650K
Net increase
(decrease) in cash and cash...
$21,621K
(539.01%↑ Y/Y)
Canceled cashflow
$3,833K
Accounts receivable
$8,761K
(80.86%↑ Y/Y)
Inventories
$2,871K
(3779.73%↑ Y/Y)
Other noncurrent
assets and liabilities
$1,420K
(41.86%↑ Y/Y)
Payments on debt, leases
and financing...
$334K
(-42.31%↓ Y/Y)
Shares repurchased for
payment of taxes on stock...
$314K
(-97.03%↓ Y/Y)
Payment of financing
costs and debt fees
$2K
Net cash used in
investing activities
-$3,766K
(59.69%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$67K
(-109.14%↓ Y/Y)
Purchases of property and
equipment
$3,766K
(-22.24%↓ Y/Y)
Buy us a coffee
AtriCure, Inc. (ATRC)
AtriCure, Inc. (ATRC)